12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

KB001-A: Phase II started

KaloBios began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 10 mg/kg IV KB001-A given up to 5 times over 16 weeks in about 180 patients. KB001-A differs from precursor molecule KB001 by a single amino acid substitution per...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >